The week in industry: Big blow for Pfizer as the Supreme Court rules against drug patent
This week: AstraZeneca signs US$1.5 billion deal, and collaborations announced to provide more people with HCV treatments and develop immunotherapies for cancer patients.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>